Literature DB >> 22975343

Alpha-1-antitrypsin inhibits nitric oxide production.

Edward D Chan1, Gregory B Pott, Philip E Silkoff, Annemarie H Ralston, Courtney L Bryan, Leland Shapiro.   

Abstract

NO is an endogenously produced gas that regulates inflammation, vascular tone, neurotransmission, and immunity. NO production can be increased by exposing cells to several endogenous and exogenous proinflammatory mediators, including IFN-γ, TNF-α, IL-1β, and LPS. As AAT has been shown to inhibit cell activation and suppress cytokine production associated with proinflammatory stimulation, we examined AAT for NO-suppressive function. In RAW 264.7 murine macrophagic cells, physiological AAT concentrations significantly inhibited combined LPS- and IFN-γ-induced NO synthesis, and NO synthesis inhibition was associated with decreased expression of iNOS, suppressed NF-κB activation, and reduced translocation of extracellular AAT into the interior of RAW 264.7 cells. CE-2072, a synthetic inhibitor of serine proteases, also suppressed NO production, iNOS expression, and NF-κB activation. However, AAT did not alter activation of intracellular MAPKs. In subjects with genetic AAT deficiency, exhaled NO was increased significantly compared with exhaled NO in healthy controls. These in vitro and in vivo studies suggest that AAT is an endogenous inhibitor of NO production. Administering AAT or AAT-like molecules may have use as a treatment for diseases associated with excessive NO production.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975343     DOI: 10.1189/jlb.0212071

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  17 in total

1.  α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.

Authors:  Patrick Geraghty; Edward Eden; Manju Pillai; Michael Campos; Noel G McElvaney; Robert F Foronjy
Journal:  Am J Respir Crit Care Med       Date:  2014-12-01       Impact factor: 21.405

Review 2.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

3.  Antioxidants and Chronic Obstructive Pulmonary Disease.

Authors:  Félix-Antoine Vézina; André M Cantin
Journal:  Chronic Obstr Pulm Dis       Date:  2018-10-08

4.  α1-antitrypsin increases interleukin-1 receptor antagonist production during pancreatic islet graft transplantation.

Authors:  Avishag Abecassis; Ronen Schuster; Galit Shahaf; Eyal Ozeri; Ross Green; David E Ochayon; Peleg Rider; Eli C Lewis
Journal:  Cell Mol Immunol       Date:  2014-04-07       Impact factor: 11.530

5.  Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells.

Authors:  Gregory B Pott; K Scott Beard; Courtney L Bryan; Daniel T Merrick; Leland Shapiro
Journal:  Front Public Health       Date:  2013-06-21

Review 6.  Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?

Authors:  Gustavo Ortiz; Juan P Salica; Eduardo H Chuluyan; Juan E Gallo
Journal:  Biol Res       Date:  2014-11-18       Impact factor: 5.612

7.  Plasma α1-antitrypsin: a neglected predictor of angiographic severity in patients with stable angina pectoris.

Authors:  Hui Zhao; Hong Liu; Lin Chai; Ping Xu; Lu Hua; Xiao-Yuan Guan; Bing Duan; Yi-Ling Huang; Yi-Shi Li
Journal:  Chin Med J (Engl)       Date:  2015-03-20       Impact factor: 2.628

8.  Oxidative status and acute phase reactants in patients with environmental asbestos exposure and mesothelioma.

Authors:  Cengizhan Sezgi; Mahsuk Taylan; Hadice Selimoglu Sen; Osman Evliyaoğlu; Halide Kaya; Ozlem Abakay; Abdurrahman Abakay; Abdullah Cetin Tanrıkulu; Abdurrahman Senyiğit
Journal:  ScientificWorldJournal       Date:  2014-01-23

Review 9.  Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.

Authors:  Friedrich Mittermayer; Erica Caveney; Claudia De Oliveira; G Alexander Fleming; Loukas Gourgiotis; Mala Puri; Li-Jung Tai; J Rick Turner
Journal:  Curr Diabetes Rev       Date:  2017

10.  Phospholipid transfer protein and alpha-1 antitrypsin regulate Hck kinase activity during neutrophil degranulation.

Authors:  Pius Ochieng; Sridesh Nath; Reane Macarulay; Edward Eden; Abdoulaye Dabo; Michael Campos; Xian-Cheng Jiang; Robert F Foronjy; Patrick Geraghty
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.